Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 5.96% | 13.96% | 14.05% | 2.92% | -2.30% |
| Total Depreciation and Amortization | 4.83% | 2.61% | 9.66% | 1.99% | -1.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.02% | 0.82% | 98.81% | 23.43% | -22.32% |
| Change in Net Operating Assets | -185.19% | 65.60% | -18.93% | -373.80% | 101.83% |
| Cash from Operations | -24.29% | 40.09% | 19.50% | -45.62% | 0.13% |
| Capital Expenditure | -82.17% | -417.65% | 89.40% | -18.19% | 1.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -20,879.84% | 107.49% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.86% | -214.39% | 174.25% | 21.28% | 3.46% |
| Cash from Investing | 148.52% | -221.34% | 136.07% | -53.07% | 7.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.39% | -68.65% | -22.42% | 17,171.52% | -99.43% |
| Repurchase of Common Stock | 85.98% | -527.70% | 78.73% | -2,427.42% | 50.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.50% | -72.55% | -21.05% | 20,022.25% | -99.53% |
| Foreign Exchange rate Adjustments | -194.01% | 1,102.40% | 74.54% | -116.25% | 251.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.90% | -168.33% | 332.16% | 73.37% | -505.28% |